Advanced search
Publication Cover
HIV Clinical Trials Volume 16, 2015 - Issue 2
Submit an article Journal homepage
1,290
Views
8
CrossRef citations to date
0
Altmetric
Original Articles

Hepatic safety in subjects with HIV-1 and hepatitis C and/or B virus: a randomized, double-blind study of maraviroc versus placebo in combination with antiretroviral agents

Juergen K. RockstrohDepartment of Medicine IUniversity of Bonn, Bonn, Germany
,
Vicente SorianoDepartment of Infectious Diseases and Internal MedicineHospital Carlos III-La Paz University Hospital, Madrid, Spain
,
Frank PlonskiGlobal Clinical DevelopmentPfizer Inc, Collegeville, PA, USA
,
Meena BansalDivision of Liver DiseasesIcahn School of Medicine at Mount Sinai, New York, NY,USA
,
Gerd FätkenheuerDepartment I of Internal MedicineUniversity Hospital Cologne, Cologne, Germany
,
Catherine B. SmallDepartment of MedicineDivision of Infectious Diseases, New York Medical College, Valhalla, NY, USA
,
David M. AsmuthDepartment of Internal MedicineUniversity of California Davis Medical Center, Sacramento, CA, USA
,
Gilles PialouxMaladies Infectieuses et TropicalesHôpital Tenon, Paris, France
,
Geoffrey MukwayaClinical Research and DevelopmentPfizer Inc, New York, NY, USA
,
Shyla JagannathaJanssen Research and Development, Janssen Pharmaceuticals, Inc., Titusville, NJ, USA
,
Jayvant HeeraClinical Sciences, Pfizer Inc, Groton, CT, USACorrespondence[email protected]
&
Juan A. PinedaUnit of Infectious Diseases, Hospital Universitario de Valme, Instituto de Investigación Biomédica de Sevilla (IBIS), Seville, Spain
 show all
Pages 72-80 | Published online: 29 Apr 2015

Citations (8)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Miao Miao, Erik De Clercq & Guangdi Li. (2020) Clinical significance of chemokine receptor antagonists. Expert Opinion on Drug Metabolism & Toxicology 16:1, pages 11-30.
Read now

Articles from other publishers (7)

Wangrui Lei, Liyuan Jia, Zheng Wang, Zhenxing Liang, Zhao Aizhen, Yanqing Liu, Ye Tian, Lin Zhao, Yawu Chen, Guangyong Shi, Zhi Yang, Yang Yang & Xuezeng Xu. (2023) CC chemokines family in fibrosis and aging: From mechanisms to therapy. Ageing Research Reviews 87, pages 101900.
Crossref
Daniel Bradshaw, Yvonne Gilleece, Sumita Verma, Iga Abramowicz, Stephen Bremner & Nicky Perry. (2020) Protocol for a phase IV, open-label feasibility study investigating non-invasive markers of hepatic fibrosis in people living with HIV-1 and non-alcoholic fatty liver disease randomised to receiving optimised background therapy (OBT) plus maraviroc or OBT alone. BMJ Open 10:7, pages e035596.
Crossref
Jason T. Blackard, Ling Kong, Susan D. Rouster, Rebekah Karns, Paul S. Horn, Shyam Kottilil, M. Tarek Shata & Kenneth E. Sherman. (2019) CCR5 receptor antagonism inhibits hepatitis C virus (HCV) replication in vitro. PLOS ONE 14:10, pages e0224523.
Crossref
Carlo Giaquinto, Muthuhadini Patience Mawela, Kulkanya Chokephaibulkit, Marinella Della Negra, Ismail Haroon Mitha, Jan Fourie, Annie Fang, Elna van der Ryst, Srinivas Rao Valluri, Manoli Vourvahis, Rebecca Yanhui Zhang-Roper, Charles Craig, Lynn McFadyen, Andrew Clark & Jayvant Heera. (2018) Pharmacokinetics, Safety and Efficacy of Maraviroc in Treatment-experienced Pediatric Patients Infected With CCR5-Tropic HIV-1. Pediatric Infectious Disease Journal 37:5, pages 459-465.
Crossref
Manuel Crespo, Jordi Navarro, Santiago Moreno, Jesus Sanz, Manuel Márquez, Javier Zamora, Antonio Ocampo, Josèc) A. Iribaren, Antonio Rivero & Josep M. Llibre. (2017) Hepatic safety of maraviroc in HIV-1-infected patients with hepatitis C and/or B co-infection. The Maraviroc Cohort Spanish Group. Enfermedades infecciosas y microbiologia clinica (English ed.) 35:8, pages 491-496.
Crossref
Manuel Crespo, Jordi Navarro, Santiago Moreno, Jesus Sanz, Manuel Márquez, Javier Zamora, Antonio Ocampo, José A. Iribaren, Antonio Rivero & Josep M. Llibre. (2017) Hepatic safety of maraviroc in HIV-1-infected patients with hepatitis C and/or B co-infection. The Maraviroc Cohort Spanish Group. Enfermedades Infecciosas y Microbiología Clínica 35:8, pages 493-498.
Crossref
Juergen K Rockstroh, Frank Plonski, Meena Bansal, Gerd Fätkenheuer, Catherine B Small, David M Asmuth, Gilles Pialoux, Rebecca Zhang-Roper, Ronnie Wang, Juan A Pineda & Jayvant Heera. (2016) Hepatic Safety of Maraviroc in Patients with HIV-1 and Hepatitis C and/or B Virus: 144-Week Results from a Randomized, Placebo-Controlled Trial. Antiviral Therapy 22:3, pages 263-269.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.